Saturday, June 1, 2013

Kentucky Board of Pharmacy Issues a Reminder About Compounding Issues

Compounding Issues
In line with FDA’s statement, pharmacists are reminded that 20 CSR
2220-2.200(9) provides:
Compounding of drug products that are commercially available
in the marketplace or that are essentially copies of commercially
available Federal [Food and] Drug Administration (FDA) approved
drug products is prohibited. There shall be sufficient
documentation within the prescription record of the pharmacy
of the specific medical need for a particular variation of a commercially
available compound.

quoted from Kentucky Board of Pharmacy June 2013 Newsletter

No comments: